NA
NAUT
Nautilus Biotechnology, Inc.
$2.38
0.00%
$302.4M
No data for this timeframe.
Vol
Market Cap$302.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders6 funds
Inst. Value$5.7M
Inst. Activity2 buys / 2 sells
Reddit Sentiment33° Cool
SEC Reports3
Press Releases1
Recent Activity
Apr 28, 2026
SEC
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as
PRESS-RELEASE — Impact 4/10
Apr 28, 2026
earnings
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
<p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDA
Apr 28, 2026
SEC
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expe
8-K — Impact 4/10
Mar 18, 2026
Press
Nautilus Biotechnology announced that Baylor College of Medicine has joined its Iterative Mapping Early Access Program,
Impact 6/10
Mar 2, 2026
Insider
Weld Gwen E sold 160,000 shares
Chief People Officer @ $0.00 ($0.00)
Mar 2, 2026
Insider
Mallick Parag sold 280,000 shares
Chief Scientist @ $0.00 ($0.00)
Mar 2, 2026
Insider
Sankar Subramanian sold 160,000 shares
Senior VP, Product Development @ $0.00 ($0.00)
Feb 26, 2026
SEC
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025, with $156.1 million
8-K — Impact 4/10
Price Targets
$4.00
+68.1% upside
Strong Buy
Current $2.38
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 | $-0.14 — $-0.14 | -17% YoY | 1 |
| Next Q | $-0.15 ▼ -7.1% | $-0.15 — $-0.15 | -36% YoY | 1 |
| Current FY | $-0.52 ▲ +6.4% | $-0.52 — $-0.51 | -10% YoY | 2 |
| Next FY | $-0.52 ▲ +5.5% | $-0.61 — $-0.43 | -1% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expe
Apr 28, 2026
MIXED
Press
6/10
Nautilus Biotechnology announced that Baylor College of Medicine has joined its Iterative Mapping Early Access Program,
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | $506.8K | TRIM |
| MORGAN STANLEY | $75.2K | ADD |
| BANK OF AMERICA CORP | $39.3K | DOUBLED |
| FMR LLC | $6.8K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Weld Gwen | A | $0.00 |
| Mar 2, 2026 | Mallick Parag | A | $0.00 |
| Mar 2, 2026 | Sankar Subramanian | A | $0.00 |
| Mar 2, 2026 | Suzuki Kentaro | A | $0.00 |
| Mar 2, 2026 | Patel Sujal | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
6 institutional holders with $5.7M total value (2,920,920 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,598,223 | $5.1M | 89.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 259,900 | $506.8K | 8.9% | TRIM -74.2% |
| 3 | MORGAN STANLEY | 38,584 | $75.2K | 1.3% | ADD +50.0% |
| 4 | BANK OF AMERICA CORP /DE/ | 20,167 | $39.3K | 0.7% | DOUBLED +2380.6% |
| 5 | FMR LLC | 3,486 | $6.8K | 0.1% | TRIM -59.7% |
| 6 | WELLS FARGO & COMPANY/MN | 560 | $1.1K | 0.0% | TRIM -61.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,007,662 | 259,900 | -74.2% | $506.8K | 2025-Q4 |
| MORGAN STANLEY | ADD | 25,728 | 38,584 | +50.0% | $75.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 813 | 20,167 | +2380.6% | $39.3K | 2025-Q4 |
| FMR LLC | TRIM | 8,660 | 3,486 | -59.7% | $6.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 619,906 | 1,007,662 | +62.6% | $851.4K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 54,577 | 25,728 | -52.9% | $21.7K | 2025-Q3 |
| FMR LLC | TRIM | 24,498 | 8,660 | -64.7% | $7.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 8,363 | 813 | -90.3% | $686.00 | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 1,443 | 560 | -61.2% | $473.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 16,320 | 470 | -97.1% | $397.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 300,456 | 619,906 | +106.3% | $449.4K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 172,161 | 54,577 | -68.3% | $39.6K | 2025-Q2 |
| FMR LLC | DOUBLED | 11,914 | 24,498 | +105.6% | $17.8K | 2025-Q2 |
| UBS Group AG | TRIM | 21,770 | 16,320 | -25.0% | $11.8K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 29,652 | 8,363 | -71.8% | $6.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 29,542 | 1,443 | -95.1% | $1.0K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 115,418 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | TRIM | 393,606 | 172,161 | -56.3% | $148.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 220,220 | 137,428 | -37.6% | $118.3K | 2025-Q1 |
| UBS Group AG | TRIM | 47,230 | 21,770 | -53.9% | $18.7K | 2025-Q1 |
| FMR LLC | ADD | 7,033 | 11,914 | +69.4% | $10.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 154,700 | 250,221 | +61.7% | $420.4K | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 81,339 | 220,220 | +170.7% | $370.0K | 2024-Q4 |
| UBS Group AG | ADD | 27,781 | 47,230 | +70.0% | $79.3K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 137,487 | — | $391.8K | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Weld Gwen E | Chief People Officer | A | 160,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Mallick Parag | Chief Scientist | A | 280,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Sankar Subramanian | Senior VP, Product Development | A | 160,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Suzuki Kentaro | Chief Marketing Officer | A | 160,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Patel Sujal M | CEO, President, and Secretary | A | 650,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Murphy Matthew B. | General Counsel | A | 160,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
PRESS-RELEASE
4/10
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with re
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago,
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025,
Feb 26, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.00 mean target
+68.1% upside
Strong Buy (3.00)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $2.38 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.14 | $-0.14 | -16.7% | +0.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.15 | $-0.15 | $-0.15 | -36.4% | -7.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.52 | $-0.52 | $-0.51 | -9.6% | +6.4% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.52 | $-0.61 | $-0.43 | -1.0% | +5.5% | 2↑ 0↓ | $0.0B | 992.9% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.140 | |
| 7d ago | $-0.145 | +0.005 |
| 30d ago | $-0.140 | |
| 60d ago | $-0.140 | |
| 90d ago | $-0.150 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Apr 28, 2026
earnings
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
<p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule p
Apr 28, 2026
earnings_calendar
NAUT Q1 2026 Earnings Scheduled — 2026-04-28
Mar 25, 2026
short_volume
Short Volume: NAUT — 61.4% short (0.3M / 0.5M)
Short: 318,091 | Exempt: 7,676 | TRF Vol: 517,815 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_volume
Short Volume: NAUT — 68.4% short (0.4M / 0.6M)
Short: 427,774 | Exempt: 49,252 | TRF Vol: 625,495 | Short Ratio: 68.4% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: NAUT — 64.9% short (0.4M / 0.6M)
Short: 376,823 | Exempt: 8,740 | TRF Vol: 580,290 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Mar 18, 2026
fda
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
<p align="center"><em>• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class
Feb 26, 2026
earnings_calendar
NAUT Q4 2025 Earnings Before Market Open — 2026-02-26